These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32096871)

  • 41. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
    McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
    Zhang L; Zhang X; Fan S; Zhang Z
    Medicine (Baltimore); 2019 Nov; 98(44):e17803. PubMed ID: 31689861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
    Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
    Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
    Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
    Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
    Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
    BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
    Miyamoto M; Takano M; Iwaya K; Shinomiya N; Goto T; Kato M; Suzuki A; Aoyama T; Hirata J; Nagaoka I; Tsuda H; Furuya K
    Br J Cancer; 2015 Feb; 112(4):739-44. PubMed ID: 25628093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
    Spentzos D; Levine DA; Ramoni MF; Joseph M; Gu X; Boyd J; Libermann TA; Cannistra SA
    J Clin Oncol; 2004 Dec; 22(23):4700-10. PubMed ID: 15505275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
    Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
    Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.